EBE Position Paper ” A Risk-based Approach to Setting Sterile Filtration Bioburden Limits”
As part of the submission supporting the request for a marketing authorisation, medicines must demonstrate that they are of appropriate quality, which often includes a demonstration of sterility. Biotechnology-derived medicinal products are typically sensitive to common methods of terminal sterilisation (sterilisation once the product has been filled into the final container) such as steam sterilisation and irradiation. They are therefore manufactured through aseptic processes where microbial contaminants are typically removed through sterile filtration. If the medicinal product contains a high level of microbial contaminants (so-called bioburden) before sterile filtration, the chance of breaching the sterilising filter is higher, which may lead to high amounts of contaminants, that might cause product safety and quality issues.